NCT04253262View on ClinicalTrials.gov

A Study of Copanlisib Combined With Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

April 3, 2020

Primary Completion Date

January 31, 2027

Study Completion Date

January 31, 2027

Conditions
Metastatic Castration-resistant Prostate Cancer
Interventions
DRUG

Rucaparib

Rucaparib (PO twice daily continuous)

DRUG

Copanlisib

Copanlisib (IV day 1, 8, 15; 28 day cycle)

Trial Locations (2)

94115

Helen Diller Family Comprehensive Cancer Center University of California San Francisco, San Francisco

02903

Lifespan Cancer Institute, Providence

Sponsors

Lead Sponsor

Brown University
All Listed Sponsors
collaborator

Rhode Island Hospital

OTHER

collaborator

The Miriam Hospital

OTHER

collaborator

Bayer

INDUSTRY

collaborator

Clovis Oncology, Inc.

INDUSTRY

lead

Brown University

OTHER